Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT06698575
Registration number
NCT06698575
Ethics application status
Date submitted
8/11/2024
Date registered
21/11/2024
Date last updated
27/03/2025
Titles & IDs
Public title
A Study to Assess the Safety, Pharmacokinetics, and Tolerability of ABI-1179 in Healthy Subjects and in Subjects Seropositive for HSV-2 With Recurrent Genital Herpes
Query!
Scientific title
A Phase 1a/1b, Blinded, Placebo-Controlled Study of the Safety, Tolerability and Pharmacokinetics of Single- and Multiple Ascending Doses of ABI-1179 in Healthy Subjects and in Subjects Who Are Seropositive for Herpes Simplex Virus Type 2 With Recurrent Genital Herpes
Query!
Secondary ID [1]
0
0
ABI-1179-101
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Recurrent Genital Herpes Simplex Type 2
0
0
Query!
Condition category
Condition code
Infection
0
0
0
0
Query!
Other infectious diseases
Query!
Skin
0
0
0
0
Query!
Other skin conditions
Query!
Infection
0
0
0
0
Query!
Sexually transmitted infections
Query!
Renal and Urogenital
0
0
0
0
Query!
Other renal and urogenital disorders
Query!
Other
0
0
0
0
Query!
Research that is not of generic health relevance and not applicable to specific health categories listed above
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - ABI-1179
Treatment: Drugs - ABI-1179 Placebo
Experimental: Part A: SAD Cohorts 1-5, ABI-1179 - Single dose of ABI-1179 (tablet) in Part A for cohorts 1-5
Placebo comparator: Part A:SAD Cohorts 1-5, Placebo - Single dose of matching placebo (tablet) in Part A for Cohorts 1-5
Experimental: Part A: (SAD) Fed Cohort 6 or 7, ABI-1179 - Single dose of ABI-1179 (tablet) in Part A for Cohort 6 or 7, food effect
Experimental: Part B: MAD Cohorts 1-4, ABI-1179 - Weekly dose ofABI-1179 (tablet) in Part B for Cohorts 1-4. May have loading dose.
Placebo comparator: Part B: MAD Cohorts 1-4 Placebo - Weekly dose of matching placebo (tablet) in Part B for Cohorts 1-4.
Treatment: Drugs: ABI-1179
Once daily tablet dosing (SAD), or weekly tablet dosing over 29 days (MAD)
Treatment: Drugs: ABI-1179 Placebo
Once daily tablet dosing (SAD), or weekly tablet dosing over 29 days (MAD)
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Area Under the Plasma Concentration Time Curve, (AUC) of ABI-1179
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
SAD Cohorts: before and at pre-specified timepoints up to 144 hours after dosing. MAD Cohorts: before and at pre-specified time points up to 8 hours after dosing.
Query!
Primary outcome [2]
0
0
Maximum Observed Plasma Concentration (Cmax) of ABI-1179
Query!
Assessment method [2]
0
0
Query!
Timepoint [2]
0
0
SAD Cohorts: before and at pre-specified timepoints up to 144 hours after dosing. MAD Cohorts: before and at pre-specified time points up to 8 hours after dosing.
Query!
Primary outcome [3]
0
0
Time to Cmax (Tmax) of ABI-1179
Query!
Assessment method [3]
0
0
Query!
Timepoint [3]
0
0
SAD Cohorts: before and at pre-specified timepoints up to 144 hours after dosing. MAD Cohorts: before and at pre-specified time points up to 8 hours after dosing.
Query!
Primary outcome [4]
0
0
Apparent Terminal Elimination Half Life ( t 1/2) ABI-1179
Query!
Assessment method [4]
0
0
Query!
Timepoint [4]
0
0
SAD Cohorts: before and at pre-specified timepoints up to 144 hours after dosing. MAD Cohorts: before and at pre-specified time points up to 8 hours after dosing.
Query!
Primary outcome [5]
0
0
Apparent Systemic Clearance (CL/F) of ABI-1179
Query!
Assessment method [5]
0
0
Query!
Timepoint [5]
0
0
SAD Cohorts: before and at pre-specified timepoints up to 144 hours after dosing. MAD Cohorts: before and at pre-specified time points up to 8 hours after dosing.
Query!
Primary outcome [6]
0
0
Apparent Volume of Distribution (Vz/F) of ABI-1179
Query!
Assessment method [6]
0
0
Query!
Timepoint [6]
0
0
SAD Cohorts: before and at pre-specified timepoints up to 144 hours after dosing. MAD Cohorts: before and at pre-specified time points up to 8 hours after dosing.
Query!
Primary outcome [7]
0
0
Dose normalized AUCs and Cmax of ABI-1179
Query!
Assessment method [7]
0
0
Query!
Timepoint [7]
0
0
SAD Cohorts: before and at pre-specified timepoints up to 144 hours after dosing. MAD Cohorts: before and at pre-specified time points up to 8 hours after dosing.
Query!
Primary outcome [8]
0
0
Proportion of subjects with adverse events (AEs), premature treatment discontinuation due to AE's and abnormal laboratory results.
Query!
Assessment method [8]
0
0
Query!
Timepoint [8]
0
0
Up to 56 days after last dose.
Query!
Secondary outcome [1]
0
0
SAD Cohorts: Comparison of Plasma AUC between fasted and fed treatments
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
MAD Cohorts: At pre-specified time points from Days 8 to 36.
Query!
Secondary outcome [2]
0
0
SAD Cohorts: Comparison of plasma Cmax between fasted and fed treatments
Query!
Assessment method [2]
0
0
Query!
Timepoint [2]
0
0
SAD Cohorts: before and at pre-specified timepoints up to 144 hours after dosing.
Query!
Secondary outcome [3]
0
0
MAD Cohort: If applicable comparison of plasma AUC and Cmax with and without loading doses
Query!
Assessment method [3]
0
0
Query!
Timepoint [3]
0
0
MAD Cohorts At pre-specified timepoints from Days 8 to 36
Query!
Secondary outcome [4]
0
0
MAD Cohorts: Difference in viral shedding rate (number of anogenital swabs positive for HSV-2 DNA/total number of swabs) across treatments.
Query!
Assessment method [4]
0
0
Query!
Timepoint [4]
0
0
MAD Cohorts: At pre-specified time points from Days 8 to 36.
Query!
Secondary outcome [5]
0
0
MAD Cohorts: in mean and median HSV-2 DNA copies/ml for swab samples positive for HSV-2 DNA across treatments
Query!
Assessment method [5]
0
0
Query!
Timepoint [5]
0
0
MAD Cohorts: At pre-specified time points from Days 8 to 36.
Query!
Secondary outcome [6]
0
0
MAD Cohorts: Difference in the proportion of swab samples with HSV-2 DNA>4log10 copies/mL across treatments (number of swabbing samples with HSV-2 DNA >4 log10 copies/mL / total number of swabs obtained).
Query!
Assessment method [6]
0
0
Query!
Timepoint [6]
0
0
MAD Cohorts: At pre-specified time points from Days 8 to 36.
Query!
Secondary outcome [7]
0
0
MAD Cohorts: Difference in number of shedding episodes during the swabbing period across treatments.
Query!
Assessment method [7]
0
0
Query!
Timepoint [7]
0
0
MAD Cohorts: At pre-specified time points from Days 8 to 36.
Query!
Secondary outcome [8]
0
0
MAD Cohorts: Difference in duration of shedding episodes during the swabbing period across treatments.
Query!
Assessment method [8]
0
0
Query!
Timepoint [8]
0
0
MAD Cohorts: At pre-specified time points from Days 8 to 36.
Query!
Secondary outcome [9]
0
0
MAD Cohorts: Difference in the subclinical shedding rate (number of swabs positive for HSV-2 DNA in the absence of lesions/total number of swabs in the absence of lesions) across treatments.
Query!
Assessment method [9]
0
0
Query!
Timepoint [9]
0
0
MAD Cohorts: At pre-specified time points from Days 8 to 36.
Query!
Secondary outcome [10]
0
0
MAD Cohorts: Difference in the lesion rate during the swabbing period across treatments.
Query!
Assessment method [10]
0
0
Query!
Timepoint [10]
0
0
MAD Cohorts: At pre-specified time points from Days 8 to 36.
Query!
Secondary outcome [11]
0
0
MAD Cohorts: Difference in lesion duration during the swabbing period across treatments
Query!
Assessment method [11]
0
0
Query!
Timepoint [11]
0
0
MAD Cohorts: At pre-specified time points from Days 8 to 36.
Query!
Secondary outcome [12]
0
0
MAD Cohorts: Difference in the recurrence rate (number of reappearances of lesions during the swabbing period/total days assessed) across treatments.
Query!
Assessment method [12]
0
0
Query!
Timepoint [12]
0
0
MAD Cohorts: At pre-specified time points from Days 8 to 36.
Query!
Eligibility
Key inclusion criteria
Part A:
* Subject has a body mass index (BMI) between =18.0 and <32.0 kg/m2
* In good health (as determined by the Investigator) based on medical history, physical examination, ECG, and clinical laboratory results.
* Female subjects must be non-pregnant and have a negative serum pregnancy test at Screening and a negative urine pregnancy test at Day-1 or Day 1 (predose).
* Agreement to comply with protocol-specified contraceptive requirements.
Part B:
* Subject has a body mass index (BMI) between =18.0 and <32.0 kg/m2
* Other than HSV infection, is in good health (as determined by the investigator) based on medical history, physical examination, ECG, and clinical laboratory results.
* Female subjects must be non-pregnant and have a negative serum pregnancy test at Screening and a negative urine pregnancy test at Day 1 (predose).
* Agreement to comply with protocol-specified contraceptive requirements
Part A and B:
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
60
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
Yes
Query!
Key exclusion criteria
* Current infection of human immunodeficiency virus (HIV), hepatitis B virus, (HBV), hepatitis C virus (HCV), acute hepatitis A virus (HAV), or acute hepatitis E virus (HEV).
* History of any illness that, in the opinion of the Investigator, might confound the results of the study, pose an additional risk in administering study drug to the subject, or condition known to interfere with the absorption /distribution/ elimination of drugs.
* History of any significant drug-related allergic reactions such as anaphylaxis, Stevens-Johnson Syndrome, urticaria, or multiple drug allergies.
* History of persistent alcohol abuse or illicit drug abuse within 3 years prior to screening.
* Has participated in a clinical study involving administration of either an investigational or a marketed drug within 30 days or 5 half-lives before screening, whatever is longer.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 1
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
8/12/2024
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
1/12/2025
Query!
Actual
Query!
Sample size
Target
146
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
A
Query!
Recruitment hospital [1]
0
0
Momentum Sunshine - Melbourne
Query!
Recruitment hospital [2]
0
0
East Sydney Doctors - Darlinghurst
Query!
Recruitment hospital [3]
0
0
Royal Melbourne Hospital - Parkville
Query!
Recruitment hospital [4]
0
0
Taylor Square Private Clinic - Surry Hills
Query!
Recruitment hospital [5]
0
0
Momentum Clinical Research - Sydney
Query!
Recruitment postcode(s) [1]
0
0
3021 - Melbourne
Query!
Recruitment postcode(s) [2]
0
0
2010 - Darlinghurst
Query!
Recruitment postcode(s) [3]
0
0
3050 - Parkville
Query!
Recruitment postcode(s) [4]
0
0
2010 - Surry Hills
Query!
Recruitment postcode(s) [5]
0
0
2010 - Sydney
Query!
Recruitment outside Australia
Country [1]
0
0
New Zealand
Query!
State/province [1]
0
0
New
Query!
Country [2]
0
0
New Zealand
Query!
State/province [2]
0
0
Auckland
Query!
Country [3]
0
0
New Zealand
Query!
State/province [3]
0
0
Christchurch
Query!
Country [4]
0
0
New Zealand
Query!
State/province [4]
0
0
Nelson
Query!
Country [5]
0
0
New Zealand
Query!
State/province [5]
0
0
Palmerston North
Query!
Country [6]
0
0
New Zealand
Query!
State/province [6]
0
0
Rotorua
Query!
Country [7]
0
0
New Zealand
Query!
State/province [7]
0
0
Upper Hutt
Query!
Country [8]
0
0
New Zealand
Query!
State/province [8]
0
0
Waikanae
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Assembly Biosciences
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This study is designed to assess safety, tolerability, and pharmacokinetics (PK) of single ascending dose (SAD) of ABI-1179 in Part A in healthy participants and multiple-ascending doses (MAD) of ABI-1179 in Part B in participants seropositive for Herpes Simplex Virus Type 2 (HSV-2) with recurrent genital herpes. Effect of food will also be evaluated in Part A.
Query!
Trial website
https://clinicaltrials.gov/study/NCT06698575
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Assembly Biosciences Assembly Biosciences
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
833-509-4583
Query!
Fax
0
0
Query!
Email
0
0
clinicaltrials@assemblybioscience.com
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results not provided in
https://clinicaltrials.gov/study/NCT06698575
Download to PDF